The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.icon
Research Grade Sotigalimab Biosimilar
Tumor necrosis factor receptor superfamily member 5,B-cell surface antigen CD40,Bp50,CD40L receptor,TNFRSF5,CDw40,CD40
Protein A or G purified from cell culture supernatant.
Please contact with the lab for this information.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6
For research use only .Not suitable for clinical or therapeutic use.